Arcadia Biosciences Future Growth

Future criteria checks 1/6

Arcadia Biosciences is forecast to grow earnings and revenue by 22.7% and 19.5% per annum respectively while EPS is expected to grow by 47.4% per annum.

Key information

22.7%

Earnings growth rate

47.4%

EPS growth rate

Food earnings growth	9.4%
Revenue growth rate	19.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	05 Apr 2024

Recent future growth updates

Recent updates

We Think Shareholders Should Be Aware Of Some Factors Beyond Arcadia Biosciences' (NASDAQ:RKDA) Profit

Nov 22

The Future Looks Bright For Arcadia Biosciences

Dec 01

Arcadia Biosciences EPS misses by $0.06

Nov 12

Earnings and Revenue Growth Forecasts

NasdaqCM:RKDA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	8	-8	N/A	N/A	1
12/31/2024	6	-11	N/A	N/A	2
12/31/2023	5	-13	-15	-15	N/A
9/30/2023	7	-18	-14	-14	N/A
6/30/2023	6	-16	-14	-14	N/A
3/31/2023	8	-20	-13	-13	N/A
12/31/2022	7	-11	-14	-14	N/A
9/30/2022	9	-17	-18	-18	N/A
6/30/2022	10	-17	-24	-23	N/A
3/31/2022	9	-21	-27	-26	N/A
12/31/2021	7	-15	-27	-26	N/A
9/30/2021	12	4	-27	-26	N/A
6/30/2021	10	-1	-26	-25	N/A
3/31/2021	9	-5	-28	-26	N/A
12/31/2020	8	-5	-33	-30	N/A
9/30/2020	1	-20	-31	-28	N/A
6/30/2020	1	-28	-28	-25	N/A
3/31/2020	1	-14	-25	-22	N/A
12/31/2019	1	-29	-19	-17	N/A
9/30/2019	1	-23	-16	-15	N/A
6/30/2019	1	-5	-16	-15	N/A
3/31/2019	1	-15	-15	-15	N/A
12/31/2018	1	-13	-14	-14	N/A
9/30/2018	2	-16	-14	-14	N/A
6/30/2018	3	-25	-12	-12	N/A
3/31/2018	3	-22	-12	-12	N/A
12/31/2017	4	-16	-14	-14	N/A
9/30/2017	3	-18	N/A	-16	N/A
6/30/2017	4	-18	N/A	-17	N/A
3/31/2017	3	-19	N/A	-17	N/A
12/31/2016	3	-20	N/A	-17	N/A
9/30/2016	4	-18	N/A	-17	N/A
6/30/2016	5	-18	N/A	-17	N/A
3/31/2016	5	-18	N/A	-17	N/A
12/31/2015	5	-21	N/A	-15	N/A
9/30/2015	7	-21	N/A	-14	N/A
6/30/2015	7	-25	N/A	-13	N/A
3/31/2015	6	-26	N/A	-15	N/A
12/31/2014	7	-22	N/A	-15	N/A
9/30/2014	6	-21	N/A	-15	N/A
6/30/2014	7	-16	N/A	-14	N/A
3/31/2014	7	-13	N/A	-10	N/A
12/31/2013	6	-13	N/A	-10	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RKDA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RKDA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RKDA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RKDA's revenue (19.5% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: RKDA's revenue (19.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if RKDA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Arcadia Biosciences Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Consensus revenue estimates fall by 27%

Consensus EPS estimates fall by 31%

Consensus EPS estimates upgraded to US$7.44 loss

Consensus revenue estimates increase by 13%, EPS downgraded

Consensus forecasts updated

Price target decreased to US$2.50

Recent updates

Consensus revenue estimates fall by 27%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Arcadia Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Insufficient new directors

Arcadia Biosciences, Inc. (Rkda) Expands Goodwheat™ Mac & Cheese with Nationwide Availability

Arcadia Biosciences, Inc. Announces the Resignation of Laura Pitlik as Chief Marketing Officer

Consensus EPS estimates fall by 31%

Consensus EPS estimates upgraded to US$7.44 loss

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Consensus revenue estimates increase by 13%, EPS downgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcadia Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Arcadia Biosciences, Inc. Launches Goodwheat into the Breakfast Category with New Better-For-You Pancake & Waffle Mixes and Single-Serve Quikcakes

First quarter 2023 earnings released: US$10.86 loss per share (vs US$8.09 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We're Hopeful That Arcadia Biosciences (NASDAQ:RKDA) Will Use Its Cash Wisely

Arcadia Biosciences, Inc. Announces CFO Changes

Consensus forecasts updated

Price target decreased to US$2.50

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Arcadia Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Arcadia Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Arcadia Biosciences Receives Non-Compliance Letter from Nasdaq

Arcadia Biosciences to raise $5M in securities offering

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Arcadia Biosciences, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$3.75

Arcadia Biosciences, Inc., Annual General Meeting, Jun 01, 2022

Consensus revenue estimates fall by 45%

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Arcadia Biosciences, Inc. Announces Executive Changes

Investor sentiment improved over the past week

Price target decreased to US$5.25

Chief Growth Officer Chris Cuvelier has left the company

Arcadia Biosciences: Market Still Unconvinced Of Its Health Offerings

We Think Shareholders Should Be Aware Of Some Factors Beyond Arcadia Biosciences' (NASDAQ:RKDA) Profit

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: US$0.098 loss per share (vs US$0.60 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.24 loss per share (vs US$1.04 loss in 2Q 2020)

Consensus EPS estimates increase to -US$0.81

Price target increased to US$5.75

Consensus revenue estimates increase to US$8.87m

Arcadia Biosciences, Inc. (NasdaqCM:RKDA) acquired Assets of Lief Holdings, LLC and Live Zola, LLC. from Lief Holdings, LLC and Live Zola, LLC for $6.1 million.

Consensus forecasts updated

Full year 2020 earnings released: US$0.47 loss per share (vs US$4.53 loss in FY 2019)

Price target raised to US$7.53

Arcadia Biosciences, Inc. Expands GoodWheat™ Patent Portfolio

Arcadia Biosciences Welcomes Debbie Carosella to Board Of Directors

New 90-day high: US$3.58

Arcadia Biosciences, Inc. announced that it expects to receive $25.146633 million in funding

New 90-day high: US$3.45

Arcadia Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $7.672668 million.

Price target lowered to US$9.33

New 90-day low: US$2.53

Analysts update estimates

The Future Looks Bright For Arcadia Biosciences

Arcadia Biosciences, Inc. Signs Hemp Distribution Agreement with Tritium 3H, Inc

Analysts lower revenue estimates to US$3.26m

Earnings beat expectations, revenue disappoints

Third quarter 2020 earnings released: US$0.60 loss per share

Bioceres Crop Solutions Corp. (AMEX:BIOX) acquired remaining 50% interest in Verdeca LLC from Arcadia Biosciences, Inc. (NasdaqCM:RKDA) for $28 million.

Arcadia Biosciences EPS misses by $0.06